Exolaunch Successfully Deploys Satellites on Historic Ariane 6 Inaugural Launch, Enhancing European Access to Space
10.7.2024 09:01:00 EEST | Business Wire | Press release
Exolaunch, the global leader in launch mission management, integration, and satellite deployment services, proudly announced the successful deployment of four satellites aboard Arianespace’s Ariane 6 maiden flight. The liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Representing customers ESA, NASA, and Spacemanic, this mission highlights Exolaunch’s crucial role in broadening access to space and supporting new launch vehicle providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709995719/en/
The historic Ariane 6 liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Photo credits: ESA, Arianespace, CNES.
This historic launch featured ESA’s ISTSat-1 and 3Cat-4, NASA’s CURIE, and Spacemanic’s GRBBeta satellites. The successful deployment of these satellites underscores Exolaunch’s commitment to facilitating groundbreaking scientific research and technological advancements through reliable and innovative satellite deployment solutions.
ESA’s ISTSat-1, developed by students at the Instituto Superior Técnico in Lisbon, aims to demonstrate ADS-B technology, validating detection capabilities and assessing antenna and receiver performance for receiving messages from commercial aircraft. 3Cat-4, a CubeSat from Universitat Politécnica de Catalunya, features a flexible microwave payload technology demonstrator with scientific objectives related to GNSS for Earth observation and AIS receiver validation.
NASA’s CURIE mission comprises two near-identical 3U CubeSats designed to explore low-frequency radio interferometry in space. These CubeSats will study solar radio bursts by maintaining a 1-3 km separation post-deployment, contributing to the understanding of heliospheric space weather and serving as a proof of concept for future space-based interferometry observatories.
Spacemanic’s GRBBeta, a 2U CubeSat, acts as a tech demonstration for the future CAMELOT constellation, aiming to detect and localize gamma-ray bursts from space. Managed by Spacemanic and led by the Technical University of Košice, this mission tests new subsystems, including an advanced GNSS positioning module and a radio modem for instant telemetry.
The successful launch of Ariane 6 represents a significant milestone for the European space industry, heralding a new era of enhanced access to space for European entities. Ariane 6 is designed to offer flexibility and cost-efficiency, making it an attractive option for various space missions. Through supporting this historic launch, Exolaunch reinforces its dedication to fostering growth and innovation in Europe’s space sector.
"Exolaunch is honored to have been part of the Ariane 6 maiden flight, working alongside Arianespace, ESA, and CNES to provide our customers with dependable access to space,” remarked Jeanne Allarie, chief commercial officer at Exolaunch. “We also extend congratulations to ESA, NASA, and Spacemanic on their successful satellite deployments. We are proud to support these innovative missions and look forward to the scientific and technological advancements they will each bring. This launch is not only a testament to the technical prowess and collaborative spirit of the European space community, but also a stepping stone towards a more robust, competitive European presence in the global space industry. We look forward to the opportunity to support future Ariane 6 launches and ensure that Europe remains at the forefront of space exploration.”
About Exolaunch
Exolaunch (Germany, USA) is a global leader in launch mission integration and deployment technologies. With a decade of flight heritage and nearly 400 satellites launched across 29 missions to date, Exolaunch leverages industry insight to tailor turnkey solutions that meet customer needs and respond to market trends. Exolaunch fulfills launch contracts for industry leaders, the world's most innovative start-ups, research institutions, government organizations, and international space agencies. The company develops and manufactures its own flight-proven and industry-leading small satellite separation systems, with the fastest-growing heritage on the market. Exolaunch promotes safe, sustainable, and responsible use of space and is committed to making space accessible for all.
For more information, please visit www.exolaunch.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709995719/en/
Contacts
For media inquiries, please contact media@exolaunch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom